Playing It Safe? Hahn's Biosimilar View

US FDA Commissioner nominee gave a general, scripted answer to a question about biologic patents, but did Stephen Hahn inadvertently go against the agency's stance on the issue?

Stephen Hahn, President Trump’s nominee for commissioner of the FDA, at his Senate confirmation hearing today
US FDA Commissioner nominee Stephen Hahn awaits the start of his Senate confirmation hearing on 20 November, where he responded to questions about biosimilars, vaping and other issues. • Source: Derrick Gingery

The US Food and Drug Administration commissioner nominee may have unintentionally got on the wrong side of some of his future colleagues with a seemingly benign comment about biosimilars and transparency.

During his 20 November confirmation hearing with the Senate Health, Education, Labor and Pensions Committee, Hahn was asked about his views on the FDA's role in preventing patent gaming. Sen....

More from Biosimilars

More from Biosimilars & Generics